Major histocompatibility complex Class II-based therapy for stroke

Abstract

This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.

Keywords: Cell death; DRmQ; cytokines; mesenchymal stem cell; mitochondrial transfer; stem cell therapy; stroke therapy.

Figure 1

This demonstrates the anti-inflammation-based therapeutic stroke targets. DRmQ robustly sequesters central and peripheral inflammation leading to a reduction in stroke-induced behavioral and histological deficits. These therapeutic effects may also be accomplished by similar anti-neuroinflammation strategies, such as stem cell transplantation and mitochondrial transfer